37.36
-3.16 (-7.80%)
| Penutupan Terdahulu | 40.52 |
| Buka | 40.32 |
| Jumlah Dagangan | 3,207,719 |
| Purata Dagangan (3B) | 1,730,396 |
| Modal Pasaran | 4,423,835,136 |
| Harga / Jualan (P/S) | 245.61 |
| Harga / Buku (P/B) | 60.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -821.41% |
| EPS Cair (TTM) | -5.26 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 912.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 727.94% |
| Nisbah Semasa (MRQ) | 6.17 |
| Aliran Tunai Operasi (OCF TTM) | -395.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -241.49 M |
| Pulangan Atas Aset (ROA TTM) | -30.11% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Cytokinetics, Incorporated | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.20 |
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.58% |
| % Dimiliki oleh Institusi | 114.67% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 120.00 (HC Wainwright & Co., 221.20%) | Beli |
| Median | 78.00 (108.78%) | |
| Rendah | 67.00 (Morgan Stanley, 79.34%) | Beli |
| Purata | 83.00 (122.16%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 40.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 10 Apr 2025 | 78.00 (108.78%) | Beli | 37.66 |
| 07 Feb 2025 | 78.00 (108.78%) | Beli | 42.76 | |
| Needham | 08 Apr 2025 | 72.00 (92.72%) | Beli | 37.66 |
| 06 Feb 2025 | 72.00 (92.72%) | Beli | 46.17 | |
| HC Wainwright & Co. | 04 Apr 2025 | 120.00 (221.20%) | Beli | 37.66 |
| 28 Feb 2025 | 120.00 (221.20%) | Beli | 46.00 | |
| Citizens Capital Markets | 03 Apr 2025 | 78.00 (108.78%) | Beli | 40.52 |
| Morgan Stanley | 13 Feb 2025 | 67.00 (79.34%) | Beli | 41.62 |
| Citigroup | 07 Feb 2025 | 86.00 (130.19%) | Beli | 42.76 |
| Stifel | 22 Jan 2025 | 80.00 (114.13%) | Beli | 46.82 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BLUM ROBERT I | - | 40.19 | -15,000 | -602,850 |
| Jumlah Keseluruhan Kuantiti Bersih | -15,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -602,850 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 40.19 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BLUM ROBERT I | Pegawai | 31 Mar 2025 | Jual (-) | 15,000 | 40.19 | 602,850 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |